The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 4 of the 9 sources its claims cite were checked for support.
Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption
Open accessAbstract
Background: Anti-dsDNA is an important biomarker for the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE). Although several assays for anti-dsDNA antibody detection are routinely used, standardization remains limited, and differences have been reported. This study aimed to compare five methods for anti-dsDNA antibody detection and to estimate their association with complement consumption. Methods: A total of 149 samples submitted for routine laboratory testing were collected and tested on five platforms: Crithidia luciliae indirect immunofluorescence test (CLIFT), addressable laser bead immunoassay (ALBIA), a high-avidity (HA) enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CIA), and a novel particle-based multi-analyte technology (PMAT). Complements C3 and C4 were available for a subset of the total samples. Results: Correlation between anti-dsDNA assays ranged from 0.94 (CIA and PMAT) to 0.65 (ALBIA and CLIFT). The AUC from the ROC analysis using CLIFT as a reference was 0.95 for PMAT, 0.94 for CIA, 0.93 for ELISA, and 0.86 for ALBIA. The highest sensitivity relative to CLIFT at a fixed specificity of 94.4% was 84.7% for CIA and ELISA, 76.3% for PMAT, and 42.4% for ALBIA. Correlation between anti-dsDNA and C3 ranged from −0.81 for ELISA to −0.51 for ALBIA. Conclusions: Different anti-dsDNA detection methods showed varying diagnostic performance and correlation and varying agreement with CLIFT and complement consumption. ELISA, CIA, and PMAT showed high correlation to each other and to CLIFT and were in strong concordance with low C3 levels. In contrast, ALBIA revealed lower clinical performance and correlation with CLIFT and complement consumption.
Overview
CoChat Summary
## TL;DR
This study compared five anti-dsDNA antibody assays in 149 routine serum samples and found that ELISA, CIA, and PMAT agreed best with each other and with CLIFT, while ALBIA performed worse. Using C3 and C4 as surrogates for disease activity, ELISA, CIA, and PMAT also showed stronger inverse correlations with complement consumption than ALBIA.
## Key findings
- Among 149 samples, 50 (33.6%) were negative across all five platforms, and 48 (32.2%) were positive across all five methods.
- Pairwise assay correlation ranged from Spearman’s ρ = 0.65 for ALBIA vs. CLIFT to 0.94 for PMAT vs. CIA.
- Using CLIFT as the reference, ROC AUCs were 0.95 for PMAT, 0.94 for CIA, 0.93 for ELISA, and 0.86 for ALBIA.
- At fixed specificity of 94.4%, sensitivity relative to CLIFT was 84.7% for CIA and ELISA, 76.3% for PMAT, and 42.4% for ALBIA.
- For complement consumption, anti-dsDNA vs. C3 correlations were strongest for ELISA (−0.81), then CLIFT (−0.76), CIA and PMAT (both −0.70), and weakest for ALBIA (−0.51); C4 showed the same ranking pattern.
## Methods
- Retrospective comparison of five anti-dsDNA assays on 149 routine serum samples collected at Labcorp; samples came from 113 female patients, 34 male patients, and 2 with missing demographic data.
- Assays tested were CLIFT, HA ELISA, ALBIA, CIA, and PMAT; Farr assay was excluded because of limited current use.
- Concordance was assessed with Spearman correlation, ROC/AUC analysis using CLIFT as the binary reference, overlap plots, and comparisons against C3/C4 values available for subsets of samples (C3 for 49, C4 for 48).
## Limitations
- The paper states that clinical data, specifically SLE diagnoses, were unavailable for the included patients.
- The paper states that complement data were available only for a limited number of patients: 49 for C3 and 48 for C4.
- Evident from the text: the sample was from routine testing at a single large U.S. reference laboratory, and the design was based on available residual samples rather than a controlled case-control cohort, which limits direct disease-level inference.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Graphics showing a change in usage of methods for anti-dsDNA testing for the years 2009–2017 based on the results of the UKNEQAS results for anti-dsDNA sample distributions [5]. In (A) the relative proportion of the different methods is shown (from 2009). In (B) the compound average growth rates (CAGR, in percent) are displayed [5]. This content is copyright of Werfen—© Werfen 2018 All Rights Reserved. Note: Different nomenclature/abbreviations were used for the following assays in this figure: IFA = immunofluorescence assay; CLIA = chemiluminescence immunoassay.](/paper-figures/9c73e634663a48f3a90437bb7d86b44d/comparison-of-five-assays-for-the-detection-of-anti-dsdna-antibodies-and-their-figure-5.jpg)
Verification
Claims the paper makes
4 Valid · 0 Not valid · 3 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, the C3 level seems to be a good surrogate indicator of disease activity in the absence of clinical data.”
§ Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption > 4. Discussion > 4.3. Correlation Between Anti-dsDNA Assays and C3 as Proxy for Disease Activity Anti-dsDNA antibody assays are not only used for the diagnosis and classification of SLE but also for the monitoring of disease activity and assessing the risk of lupus nephritis (LN). While some assays are particularly useful for the diagnosis of SLE, others might be superior to assess active disease (flares) [22,23]. A decrease in C3 levels is often associated with increased disease activity in lupus. When the disease flares up, it can lead to the consumption and depletion of complement proteins like C3, as they are involved in immune response. Several studies investigated the inverse correlation between the C3 level and disease activity. Zhang et al. [24] found a moderate discrimination to predict SLE disease activity, while the study of Shang et al. [25] resulted in the same correlation between SLEDAI or C3 and anti-dsDNA antibodies. A more recent publication investigated 175 sera from 99 patients with SLE, 31 patients with other connective tissue diseases (CTD), and 20 healthy individuals (HI) [26]. The samples were tested for antibodies against dsDNA, C1q, nucleosomes, and histones and for C3 and C4 complement components. Multiple linear regression analysis demonstrated that disease activity in SLE could be predicted by the levels of antibodies against dsDNA determined by standard (p < 0.05) and HA ELISA (p < 0.001) and inversely associated with the concentration of C3 (p < 0.001). Thus, the C3 level seems to be a good surrogate indicator of disease activity in the absence of clinical data. Although C3 data was only available for 49 of the patients included in the study, the results showed a negative correlation between C3 and anti-dsDNA measured by the different assays and different levels of correlation between C3 and anti-dsDNA levels based on the assay used, with the highest correlation for the ELISA (0.81), followed by CLIFT (0.76), CIA (0.70), PMAT (0.70), and finally ALBIA (0.51). An inverse association with C4 was also observed, however, with lower correlation coefficient values compared to that of C4. The main limitations of our study were the lack of available clinical data (specifically SLE diagnoses) for the included patients, as well as the limited number of patients with available complement C3 and C4 data. However, a significant strength lies in the number and variety of anti-dsDNA methods and platforms employed, which accurately represent the reality of real-world laboratory settings. In addition, the samples in this study originate from routine testing at a large U.S. reference laboratory, which gives a perspective of a real-world clinical testing environment, as opposed to a controlled study design with predefined cases and controls. This approach enhances the generalizability of our findings by capturing a broader and more diverse patient population, including individuals at varying disease stages and with heterogeneous clinical presentations—conditions that are often challenging to assess across different immunological methods. This allows for the evaluation of test performance and biomarker patterns under conditions that mirror actual clinical practice, thereby increasing the relevance and potential use of the results. Lastly, this study provides valuable insights into the utilization and application of various anti-dsDNA diagnostic techniques, highlighting the importance of understanding their technical differences in the context of their use for screening versus confirmatory purposes and addressing scenarios where the use of multiple methods may not be feasible.
What the sources say
- Not checked — no full text of the sourcecites [24] Zhang, 2022, Potential biomarkers for diagnosis and assessment of disease activity in systemic lupus erythematosus, Int. Immunopharmacol. source
- Partly supportedcites [25] Shang, 2021, Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity, Immun. Inflamm. Dis. sourceExperimental — accuracy not yet measured
The Results section reports that C3 levels were negatively associated with SLE disease activity scores, and the Discussion says C3 could reflect disease activity. The paper does not evaluate C3 as a surrogate when clinical data are absent; it also cautions that changes in C3 were not sensitive enough to monitor treatment response. Page numbers were not available in our copy. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [26] Andrejevic, 2013, Immunoserological parameters in SLE: High-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity, Clin. Rheumatol. source
hedgedstates an associationn = 49 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Due to the stringent washing procedure, made possible through the wash steps with magnetic fixation of the beads, this assay is highly specific for SLE, as most low-avidity antibodies are removed.”
§ Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption > 1. Introduction
What the sources say
- Partly supportedcites [10] Mahler, 2016, Detection of autoantibodies using chemiluminescence technologies, Immunopharmacol. Immunotoxicol. sourceExperimental — accuracy not yet measured
The assay-characteristics table (page unavailable) describes the QUANTA Flash dsDNA assay as having high specificity for SLE, and the assay-principle section says its beads are washed several times. The paper does not say that stringent washing causes that specificity by removing most low-avidity antibodies; it also does not extend the SLE-specific finding to CIA assays generally. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“(Spearman’s ρ: −0.812 to −0.510; p ≤ 0.0001).”
§ Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption > 3. Results > 3.3. Correlation Between Anti-dsDNA Assays and Complements C3 and C4
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Correlation between anti-dsDNA assays ranged from 0.94 (CIA and PMAT) to 0.65 (ALBIA and CLIFT).”
- Also stated in: § 3.2. Correlation Between Anti-dsDNA Assays · plain
“The quantitative concordance as expressed by Spearman’s ρ (rho) coefficient varied between 0.65 (ALBIA vs. CLIFT) and 0.94 (PMAT vs. CIA) (Table 2; Figure 2).”
§ Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption > Abstract Background: Anti-dsDNA is an important biomarker for the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE). Although several assays for anti-dsDNA antibody detection are routinely used, standardization remains limited, and differences have been reported. This study aimed to compare five methods for anti-dsDNA antibody detection and to estimate their association with complement consumption. Methods: A total of 149 samples submitted for routine laboratory testing were collected and tested on five platforms: Crithidia luciliae indirect immunofluorescence test (CLIFT), addressable laser bead immunoassay (ALBIA), a high-avidity (HA) enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CIA), and a novel particle-based multi-analyte technology (PMAT). Complements C3 and C4 were available for a subset of the total samples. Results: Correlation between anti-dsDNA assays ranged from 0.94 (CIA and PMAT) to 0.65 (ALBIA and CLIFT). The AUC from the ROC analysis using CLIFT as a reference was 0.95 for PMAT, 0.94 for CIA, 0.93 for ELISA, and 0.86 for ALBIA. The highest sensitivity relative to CLIFT at a fixed specificity of 94.4% was 84.7% for CIA and ELISA, 76.3% for PMAT, and 42.4% for ALBIA. Correlation between anti-dsDNA and C3 ranged from −0.81 for ELISA to −0.51 for ALBIA. Conclusions: Different anti-dsDNA detection methods showed varying diagnostic performance and correlation and varying agreement with CLIFT and complement consumption. ELISA, CIA, and PMAT showed high correlation to each other and to CLIFT and were in strong concordance with low C3 levels. In contrast, ALBIA revealed lower clinical performance and correlation with CLIFT and complement consumption.
plainstates an associationn = 149- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.2. Correlation Between Anti-dsDNA Assays · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“followed by 15 (10.1%) samples positive on PMAT, CIA, and ALBIA.”
§ Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption > 3. Results > 3.1. Frequency and Intersection of Anti-dsDNA Positivity Across Platforms
plainn = 15- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
10 more claims
Create a free account to see all 38 claims and every source verdict.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 3
Citations
Cites
UpSet: Visualization of Intersecting Sets
Lex, A., Gehlenborg, N., Strobelt, H., Vuillemot, R., & Pfister, H. (2014) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2014.2346248 · Cited by 2,323
Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214819 · Cited by 1,612 · cited 2×
“Anti-dsDNA (double-stranded DNA) antibodies are highly specific markers and are part of the classification criteria for systemic lupus erythematosus (SLE) [1].”
Villalta, D., Bizzaro, N., Bassi, N., Zen, M., Gatto, M., Ghirardello, A., Iaccarino, L., Punzi, L., & Doria, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071458 · Cited by 103 · cited 1×
“Although IgM and IgA antibodies are also present, their clinical relevance remains poorly understood [2–4].”
Complement as a Biomarker for Systemic Lupus Erythematosus
Ayano, M., & Horiuchi, T. (2023) · Biomolecules · doi:10.3390/biom13020367 · Cited by 100 · cited 1×
“In addition to anti-dsDNA antibodies, complement status represents a very important biomarker in SLE and is known to play a role in disease pathogenesis [12].”
Mummert, E., Fritzler, M. J., Sjöwall, C., Bentow, C., & Mahler, M. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.05.014 · Cited by 86 · cited 4×
“Several assays can detect anti-dsDNA antibodies in a clinical setting [5,6].”
InfluentialSelf-citationIgM Antibodies Against dsDNA in SLE
Witte, T. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8046-x · Cited by 79
Andrejevic, S., Jeremic, I., Sefik-Bukilica, M., Nikolic, M., Stojimirovic, B., & Bonaci-Nikolic, B. (2013) · Clinical Rheumatology · doi:10.1007/s10067-013-2330-3 · Cited by 56 · cited 1×
“A more recent publication investigated 175 sera from 99 patients with SLE, 31 patients with other connective tissue diseases (CTD), and 20 healthy individuals (HI) [26].”
Shang, X., Ren, L., Sun, G., Yu, T., Yao, Y., Wang, L., Liu, F., Zhang, L., He, X., & Liu, M. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.401 · Cited by 51 · cited 1×
“Zhang et al. [24] found a moderate discrimination to predict SLE disease activity, while the study of Shang et al. [25] resulted in the same correlation between SLEDAI or C3 and anti-dsDNA antibodies.”
Detection of autoantibodies using chemiluminescence technologies
Mahler, M., Bentow, C., Serra, J., & Fritzler, M. J. (2016) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1077461 · Cited by 47 · cited 1×
“Chemiluminescence immunoassay (CIA): This modern technology is based on antigen-coated paramagnetic beads and chemiluminescence as the detection method [10].”
Villalta, D., Romelli, P. B., Savina, C., Bizzaro, N., Tozzoli, R., Tonutti, E., Ghirardello, A., & Doria, A. (2003) · Lupus · doi:10.1191/0961203303lu277oa · Cited by 45
Cited by
Deng, J., Zhang, Z., Lai, Y., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-41028-x
Ogrič, M., Čučnik, S., & Lakota, K. (2026) · Diagnostics · doi:10.3390/diagnostics16162612
“Overall, the evidence strongly supports an integrated, multi-assay testing approach as the most robust strategy for the accurate detection of clinically meaningful high-avidity anti-dsDNA antibodies [14,15,22].”
Irure‐Ventura, J., Sánchez, R. G., Mota‐Pérez, N., Estefanía, R. C., Comins‐Boo, A., Merino-Fernández, A. I., Hernández-Hernández, J. L., Martínez-Taboada, V. M., & López‐Hoyos, M. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-0870
Metadata
- Authors
- Ricchiuti, V., Obney, J., Holloway, B., Aure, M. A., Shapiro, M., Bentow, C., & Mahler, M.
- Affiliations
- LabCorp (United States) (US)
- Werfen (United States) (US)
- Research and Development, Werfen Autoimmunity, San Diego, CA 92131, USA
- Corresponding author
- Ricchiuti, Vincent
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2025-09-24
- Volume
- 15
- Issue
- 19
- Pages
- 2430
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC12523399
- OpenAlex
- W4414479530
- Cited by
- 3
- References
- 24
- Citations by year
- 2026: 3
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- anti-dsDNA antibodies, systemic lupus erythematosus, complement consumption, complement C3, C4, assay comparison, indirect immunofluorescence, chemiluminescence immunoassay, diagnostic performance, standardization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption. https://app.cochat.ai/papers/10.3390/diagnostics15192430
- The paper
- Ricchiuti, V., Obney, J., Holloway, B., Aure, M. A., Shapiro, M., Bentow, C., & Mahler, M. (2025). Comparison of Five Assays for the Detection of Anti-dsDNA Antibodies and Their Correlation with Complement Consumption. Diagnostics. https://doi.org/10.3390/diagnostics15192430
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.